Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Surface Oncology, Inc.    SURF

SURFACE ONCOLOGY, INC.

(SURF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Surface Oncology, Inc.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

Number of employees : 49 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Tumor Microenvironment59.42100%15.36100% -74.15%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States59.42100%15.36100% -74.15%
Managers
NameAgeSinceTitle
J. Jeffrey Goater432018President, Chief Executive Officer & Director
Daniel Lynch602018Executive Chairman
Jessica Fees47-Treasurer, Chief Financial & Accounting officer
Vito J. Palombella, Dr.562016Chief Scientific Officer
Robert W. Ross, Dr.452016Chief Medical Officer
Alison M. O'Neill, Dr.-2018Senior Vice President-Clinical Development
Dave S. Grayzel, Dr.51-Independent Non-Executive Director
Armen B. Shanafelt, Dr.592014Independent Non-Executive Director
Charles Elliott Sigal, Dr.672018Independent Non-Executive Director
Cameron Geoffrey McDonough, Dr.482018Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 39,906,066 39,232,706 98.3% 0 0.0% 98.3%
Shareholders
NameEquities%
Ecor1 Capital LLC 5,033,861 12.6%
Atlas Venture, Inc. 4,645,453 11.6%
VHCP Management LLC 3,877,895 9.72%
Lilly Ventures Management Co. LLC 3,447,817 8.64%
NEA Management Co. LLC 3,315,149 8.31%
BVF Partners LP 2,038,528 5.11%
Avidity Partners Management LP 1,478,699 3.71%
Ghost Tree Capital LLC 700,000 1.75%
FIL Investment Advisors (UK) Ltd. 647,317 1.62%
Victory Capital Management, Inc. (Investment Management) 601,458 1.51%
Company contact information
Surface Oncology, Inc.
50 Hampshire Street
8th floor
Cambridge, MA 02139

Phone : +1.617.714.4096
Web : http://www.surfaceoncology.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
SURFACE ONCOLOGY, INC.347.34%336
GILEAD SCIENCES, INC.-6.79%75 938
REGENERON PHARMACEUTICALS55.31%61 364
VERTEX PHARMACEUTICALS0.71%57 436
WUXI APPTEC CO., LTD.60.41%38 230
BEIGENE, LTD.81.90%27 326
GENMAB A/S55.65%23 862
BIONTECH SE177.21%22 369
HUALAN BIOLOGICAL ENGINEERING INC.111.92%15 643
ARGENX SE57.52%12 615
MYOKARDIA, INC.204.51%11 834
SAREPTA THERAPEUTICS, INC.9.11%11 053
NEUROCRINE BIOSCIENCES, INC.-6.33%9 390
MIRATI THERAPEUTICS, INC.51.24%8 681
ASCENDIS PHARMA A/S12.54%8 330
BIOCON LIMITED49.10%7 075
EXELIXIS, INC.28.09%6 974
ACCELERON PHARMA INC.117.30%6 901
PEPTIDREAM INC.-11.79%5 889
ULTRAGENYX PHARMACEUTICAL INC.113.42%5 523
ARROWHEAD PHARMACEUTICALS, INC.-21.05%5 123